Stride Bio Scientific

StrideBio is a biotechnology company specializing in the development of next-generation adeno-associated virus (AAV) gene therapies. The company's proprietary STRIVE (Structure-inspired Virus Engineering) platform utilizes advanced structural biology and capsid engineering to create novel AAV vectors designed to evade neutralizing antibodies and improve tissue-specific targeting. StrideBio's pipeline focuses on rare genetic diseases, particularly those affecting the central nervous system and cardiovascular system, including Rett syndrome and Friedreich's ataxia. In April 2023, the company's platform assets and capsid library were acquired by Ginkgo Bioworks to enhance their end-to-end gene therapy services. StrideBio was originally founded based on research from the University of North Carolina at Chapel Hill and the University of Florida.